These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 32417467)

  • 1. A new medium-throughput screening design approach for the development of hydroxymethylnitrofurazone (NFOH) nanostructured lipid carrier for treating leishmaniasis.
    de Souza A; Yukuyama MN; Barbosa EJ; Monteiro LM; Faloppa ACB; Calixto LA; de Barros Araújo GL; Fotaki N; Löbenberg R; Bou-Chacra NA
    Colloids Surf B Biointerfaces; 2020 Sep; 193():111097. PubMed ID: 32417467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hydroxymethylnitrofurazone lymphatic uptake with nanostructured lipid carrier after oral administration in rats.
    Souza A; Scarim CB; Cotrim PC; Junior FB; Rocha BA; Calixto LA; Correia CJ; de Barros Araújo GL; Löbenberg R; Bou-Chacra NA; Breithaupt-Faloppa AC
    Nanomedicine (Lond); 2024 Feb; 19(4):293-301. PubMed ID: 38270378
    [No Abstract]   [Full Text] [Related]  

  • 3. Development and optimization of sulforaphane-loaded nanostructured lipid carriers by the Box-Behnken design for improved oral efficacy against cancer: in vitro, ex vivo and in vivo assessments.
    Soni K; Rizwanullah M; Kohli K
    Artif Cells Nanomed Biotechnol; 2018; 46(sup1):15-31. PubMed ID: 29183147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting Leishmania amazonensis amastigotes through macrophage internalisation of a hydroxymethylnitrofurazone nanostructured polymeric system.
    Monteiro LM; Löbenberg R; Ferreira EI; Cotrim PC; Kanashiro E; Rocha M; Chung MC; Bou-Chacra N
    Int J Antimicrob Agents; 2017 Jul; 50(1):88-92. PubMed ID: 28454918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, characterization and in vivo evaluation of nanostructured lipid carriers (NLC) as a new drug delivery system for hydrochlorothiazide oral administration in pediatric therapy.
    Cirri M; Maestrini L; Maestrelli F; Mennini N; Mura P; Ghelardini C; Di Cesare Mannelli L
    Drug Deliv; 2018 Nov; 25(1):1910-1921. PubMed ID: 30451015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chlorogenic acid stabilized nanostructured lipid carriers (NLC) of atorvastatin: formulation, design and in vivo evaluation.
    Khan S; Baboota S; Ali J; Narang RS; Narang JK
    Drug Dev Ind Pharm; 2016; 42(2):209-20. PubMed ID: 26016780
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and evaluation of a cedrol-loaded nanostructured lipid carrier system for in vitro and in vivo susceptibilities of wild and drug resistant Leishmania donovani amastigotes.
    Kar N; Chakraborty S; De AK; Ghosh S; Bera T
    Eur J Pharm Sci; 2017 Jun; 104():196-211. PubMed ID: 28400285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral delivery of ursolic acid-loaded nanostructured lipid carrier coated with chitosan oligosaccharides: Development, characterization, in vitro and in vivo assessment for the therapy of leishmaniasis.
    Das S; Ghosh S; De AK; Bera T
    Int J Biol Macromol; 2017 Sep; 102():996-1008. PubMed ID: 28465178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and Biodistribution of Thymoquinone-loaded Nanostructured Lipid Carrier After Oral and Intravenous Administration into Rats.
    Zakarial Ansar FH; Latifah SY; Wan Kamal WHB; Khong KC; Ng Y; Foong JN; Gopalsamy B; Ng WK; How CW; Ong YS; Abdullah R; Aziz MY
    Int J Nanomedicine; 2020; 15():7703-7717. PubMed ID: 33116496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of hydroxymethylnitrofurazone and its parent drug nitrofurazone in rabbits.
    Nogueira Filho MA; Padilha EC; Campos ML; Pontes Machado DV; Davanço MG; Pestana KC; Chin CM; Peccinini RG
    Drug Metab Lett; 2013 Mar; 7(1):58-64. PubMed ID: 23957951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Co-delivery of buparvaquone and polymyxin B in a nanostructured lipid carrier for leishmaniasis treatment.
    Monteiro LM; Löbenberg R; Fotaki N; de Araújo GLB; Cotrim PC; Bou-Chacra N
    J Glob Antimicrob Resist; 2019 Sep; 18():279-283. PubMed ID: 31202979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Buparvaquone Nanostructured Lipid Carrier: Development of an Affordable Delivery System for the Treatment of Leishmaniases.
    Monteiro LM; Löbenberg R; Cotrim PC; Barros de Araujo GL; Bou-Chacra N
    Biomed Res Int; 2017; 2017():9781603. PubMed ID: 28255558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipid based nanocarrier system for the potential oral delivery of decitabine: formulation design, characterization, ex vivo, and in vivo assessment.
    Neupane YR; Srivastava M; Ahmad N; Kumar N; Bhatnagar A; Kohli K
    Int J Pharm; 2014 Dec; 477(1-2):601-12. PubMed ID: 25445972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of hydroxymethylnitrofurazone, a promising new prodrug for Chagas' disease treatment.
    Serafim EO; Silva AT; Moreno Ade H; Vizioli Ede O; Ferreira EI; Peccinini RG; Ribeiro ML; Chung MC
    Antimicrob Agents Chemother; 2013 Dec; 57(12):6106-9. PubMed ID: 24080661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel oral delivery system consisting in "drug-in cyclodextrin-in nanostructured lipid carriers" for poorly water-soluble drug: vinpocetine.
    Lin C; Chen F; Ye T; Zhang L; Zhang W; Liu D; Xiong W; Yang X; Pan W
    Int J Pharm; 2014 Apr; 465(1-2):90-6. PubMed ID: 24530388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and tissue distribution of an orally administered mucoadhesive chitosan-coated amphotericin B-Loaded nanostructured lipid carrier (NLC) in rats.
    Tan JSL; Roberts C; Billa N
    J Biomater Sci Polym Ed; 2020 Feb; 31(2):141-154. PubMed ID: 31612804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Formulation And Evaluation Of Nanostructured Lipid Carriers (NLCs) Of 20(S)-Protopanaxadiol (PPD) By Box-Behnken Design.
    Kim MH; Kim KT; Sohn SY; Lee JY; Lee CH; Yang H; Lee BK; Lee KW; Kim DD
    Int J Nanomedicine; 2019; 14():8509-8520. PubMed ID: 31749618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancement of S(+)-zaltoprofen oral bioavailability using nanostructured lipid carrier system.
    Pham TMA; Lee DH; Na YG; Jin M; Jung M; Kim HE; Yoo H; Won JH; Lee JY; Baek JS; Han SC; Lee HK; Cho CW
    Arch Pharm Res; 2022 Nov; 45(11):822-835. PubMed ID: 36307644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic implementation of quality-by-design (QbD) to develop NSAID-loaded nanostructured lipid carriers for ocular application: preformulation screening studies and statistical hybrid-design for optimization of variables.
    Rathod VR; Shah DA; Dave RH
    Drug Dev Ind Pharm; 2020 Mar; 46(3):443-455. PubMed ID: 32037896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fabrication and Characterization of Timolol Maleate and Brinzolamide Loaded Nanostructured Lipid Carrier System for Ocular Drug Delivery.
    Shrivastava N; Khan S; Baboota S; Ali J
    Curr Drug Deliv; 2018; 15(6):829-839. PubMed ID: 29189155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.